|
Q4 FY2026
As of Jun 30, 2026
|
Q3 FY2026
As of Mar 31, 2026
|
Q2 FY2026
As of Dec 31, 2025
|
Q1 FY2026
As of Sep 30, 2025
|
Q4 FY2025
As of Jun 30, 2025
|
Q3 FY2025
As of Mar 31, 2025
|
Q2 FY2025
As of Dec 31, 2024
|
Q1 FY2025
As of Sep 30, 2024
|
Q4 FY2024
As of Jun 30, 2024
|
Q3 FY2024
As of Mar 31, 2024
|
Q2 FY2024
As of Dec 31, 2023
|
Q1 FY2024
As of Sep 30, 2023
|
Q4 FY2023
As of Jun 30, 2023
|
Q3 FY2023
As of Mar 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS: | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash | ||||||||||||||
| Prepayments | ||||||||||||||
| Deferred offering costs | ||||||||||||||
| Prepayment | ||||||||||||||
| Total current assets | ||||||||||||||
| Total Assets | ||||||||||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY: | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Bank overdraft | ||||||||||||||
| Accrued expenses | ||||||||||||||
| Contract liabilities | ||||||||||||||
| Total current liabilities | ||||||||||||||
| Total Liabilities | ||||||||||||||
| Shareholders’ Equity: | ||||||||||||||
| Ordinary shares, $0.00001 par value; 500,000,000 shares authorized; 21,500,000 shares issued and outstanding as of June 30, 2026 and 2025 | ||||||||||||||
| Additional paid-in capital | ||||||||||||||
| Accumulated deficit | ||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||
| Total Shareholders’ (Deficit)/Equity | ||||||||||||||
| Total Liabilities and Shareholders’ Equity | ||||||||||||||
Loading...
